In 2010 OPKO out-licensed Rolapitant for the treatment of nausea and vomiting due to cancer treatment. Over 1000 patients have been evaluated in phases 1 & 2, with great results, and phase 3 results are expected in 2013. OPKO would be entitled to payments up to $121M and double digit tiered royalties.
To give you a general idea as to valuation for only 2 of the above items, world wide testing for next generation prostate markers is a 2 billion market. European approval of the Vitamin D test is expected in 2012 with US approval expected shorter thereafter. 100M tests per year equates to a 5 billion market. The aforesaid estimates were taken from the companies website. Amazingly, this is only the tip of the iceberg.